Bank of America’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-561
Closed -$392 8379
2023
Q4
$392 Hold
561
﹤0.01% 7307
2023
Q3
$386 Hold
561
﹤0.01% 7345
2023
Q2
$1.35K Buy
561
+193
+52% +$824 ﹤0.01% 7200
2023
Q1
$2.96K Sell
368
-201
-35% -$2.67K ﹤0.01% 7167
2022
Q4
$6.73K Buy
569
+5
+0.9% +$57 ﹤0.01% 7005
2022
Q3
$8K Hold
564
﹤0.01% 7294
2022
Q2
$20K Sell
564
-23
-4% -$718 ﹤0.01% 7191
2022
Q1
$24K Buy
587
+93
+19% +$3.99K ﹤0.01% 7460
2021
Q4
$21K Buy
494
+309
+167% +$19.3K ﹤0.01% 7508
2021
Q3
$13K Buy
185
+27
+17% +$1.98K ﹤0.01% 7514
2021
Q2
$12K Buy
158
+1
+0.6% +$61 ﹤0.01% 7267
2021
Q1
$10K Hold
157
﹤0.01% 7020
2020
Q4
$5K Hold
157
﹤0.01% 6833
2020
Q3
$9K Hold
157
﹤0.01% 6487
2020
Q2
$6K Hold
157
﹤0.01% 6545
2020
Q1
$4K Hold
157
﹤0.01% 6552
2019
Q4
$8K Hold
157
﹤0.01% 6694
2019
Q3
$8K Sell
157
-19
-11% -$1.36K ﹤0.01% 6769
2019
Q2
$16K Sell
176
-7
-4% -$851 ﹤0.01% 6628
2019
Q1
$27K Buy
183
+26
+17% +$5.03K ﹤0.01% 6418
2018
Q4
$25K Hold
157
﹤0.01% 6434
2018
Q3
$39K Buy
157
+85
+118% +$20.1K ﹤0.01% 6316
2018
Q2
$16K Buy
72
+1
+1% +$268 ﹤0.01% 6572
2018
Q1
$18K Hold
71
﹤0.01% 6419
2017
Q4
$22K Hold
71
﹤0.01% 6389
2017
Q3
$26K Sell
71
-4
-5% -$1.42K ﹤0.01% 6178
2017
Q2
$27K Buy
+75
New +$22.5K ﹤0.01% 6126
2016
Q4
Sell
-3
Closed -$1K 7400
2016
Q3
$1K Hold
3
﹤0.01% 6992
2016
Q2
$1K Hold
3
﹤0.01% 7026
2016
Q1
$1K Sell
3
-2
-40% -$715 ﹤0.01% 6887
2015
Q4
$2K Buy
+5
New +$1.57K ﹤0.01% 7121
2015
Q2
Sell
-29
Closed -$8K 7464
2015
Q1
$8K Buy
+29
New +$12.5K ﹤0.01% 6383
2014
Q4
Sell
-21
Closed -$7K 8045
2014
Q3
$7K Sell
21
-4
-16% -$1.17K ﹤0.01% 7468
2014
Q2
$8K Buy
+25
New +$9.82K ﹤0.01% 7546

Other funds holding DMK

Bank of America's DMK Position: Q1 2024 in Review

Bank of America sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 561 shares — an estimated $392 sold.

Bank of America first reported a position in DMK in Q2 2014 and held it in 34 quarters. The position peaked at $39K in Q3 2018. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.

  • Bank of America reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bank of America sold 561 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $392.
  • Bank of America first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2014 and held it in 34 quarters.
  • Bank of America's DMK Pharmaceuticals Corporation Common Stock position peaked at $39K in Q3 2018.
  • 3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.

Based on Bank of America's 13F filing for Q1 2024, filed 15 May 2024.